subject: Chinese Plant Extracts Face New Challenges Exporting To The U.s. [print this page] With the continuous penetration of international financial crisis, Europe and America's pharmaceutical industry suffered a severe blow. Total exports of Chinese extract, herbal medicine and other varieties become continue declined. In the combined effects of multiple crises, Chinese plant extracts enterprises will face unprecedented pressures. In 2009, the U.S. APHIS revised the Lacey Act and decided to implement it in phases. Because the U.S. is a major exporter of plant extracts for China, therefore implementation of the regulations will inevitably has an impact on the export of plant extracts of China.
The thrust of the wildlife protection law in the United States is to combat the illegal trade of wild animals and plants. Lacey Act further expanded the scope of protection of endangered plants and animals from extended to the protection of the entire wild animals and plants and their products. In addition, the products in violation of the regulations will be taken to the seizure, fines and forfeiture measures, false information, error identification, and such acts should take appropriate punitive measures. As a result, the scope of protection of the new regulations goes far beyond the circle of endangered biological species, related to more types of goods, the export of Chinese plant extract is a potential threat.
In plant extracts products exporting from China, many docetaxel plants have been carried out with large-scale cultivation, such as licorice, Artemisia annual, green tea, ephedra, etc., but there are still some products derived from wild plants such as centella asiatica, prostitution hopanes, etc., in the coexistence of wild and planting resources. Many plant extract varieties, due to the uncertainty of the number and size of the export demand for exports of the country of destination is not the same, and there is no implementation of the large area planted. Is expected that these products are exported to the U.S. in the future will be subject to certain restrictions.
Implementation of the new regulations will restrict China plant extracts exporting to the U.S to some extent, and the spread of the financial crisis will also give the Chinese plant extracts export to wear the yoke. Financial crisis, the decline in spending power of ordinary people in the United States, the consumption of products derived from plant extracts also decreased. Can be predicted that the financial crisis Chinese plant extract products export to USA and the United States will face more severe challenges.
The industry believes that the U.S. regulations require importers submit plant and product returns, and this necessarily translate into a request of the importer to export enterprises to provide relevant information. Detailed to provide the botanical name of the product, the origin country in operation there is a big difficulty, especially involving some legitimacy to prove. Therefore, the requirements that so many irinotecan products need import declaration virtually increase many import declaration and verification link. It will increase the export costs of Chinese enterprises and is bound to produce a constraint for Chinese products in the United States markets.
In addition, the specific implementation of the new regulations scope and rules for the operation are not yet clear. The legal proceedings are different between the states. The implementations of grasps are different too. Operational complexity and unknown factors also potential impact on Chinese products exported to the United States. Experts have warned that China's export enterprises should pay close attention to the progress and dynamics of the United States in implementation of the new regulations by the U.S. importer or the relevant authorities. For the unreasonable and unclear problems in regulations, China can have feedback representations to the United States and makes efforts to reduce the negative impact on China's export trade during the implementation time.
